{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:21:36Z","timestamp":1784308896592,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic cancer (PC) is an aggressive malignant disease with poor prognosis, often diagnosed late, progressing rapidly, and resistant to chemotherapy. Although small molecule inhibitors (SMIs) show promise in preclinical PC models, translation into clinics remains challenging. In this systematic review and meta-analysis, we screened literature according to predefined criteria to identify preclinical PC mouse models used for SMI therapy in primary tumors, assess reporting quality, and evaluate tumor reduction, heterogeneity and publication bias. Following a pre-registered PROSPERO protocol (CRD42022314932), literature searches in PubMed and Embase yielded 2972 articles, of which 297 were included for data extraction. Most studies used PDX models or MiaPaCa-2 and PANC-1 cell lines as heterotopic xenografts, with Foxn1\n                    <jats:sup>nu<\/jats:sup>\n                    mice representing the predominant genetic background. Reporting quality, assessed using the ARRIVE guidelines, revealed substantial gaps, particularly in blinding (94% not reported), inclusion\/exclusion criteria (49% not reported), and randomization (34% not reported). Meta-regression accounted for part of the observed heterogeneity and funnel plot asymmetry was consistent with publication bias. This study emphasized the large variability among preclinical PC mouse models used to investigate SMI candidates and the complexity of model choice highlighting the critical need for improved reporting practices to enhance reproducibility and reliability of preclinical tumor models.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-25191-1","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:27:30Z","timestamp":1761557250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical pancreatic cancer mouse models for treatment with small molecule inhibitors: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Sophia","family":"Villwock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalda","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"25191_CR1","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.21873\/anticanres.13026","volume":"38","author":"M Aslan","year":"2018","unstructured":"Aslan, M., Shahbazi, R., Ulubayram, K. & Ozpolat, B. Targeted therapies for pancreatic cancer and hurdles ahead. Anticancer Res. 38, 6591\u20136606. https:\/\/doi.org\/10.21873\/anticanres.13026 (2018).","journal-title":"Anticancer Res."},{"key":"25191_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2020.10.007","volume":"160","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology 160, 744\u2013754 (2021).","journal-title":"Gastroenterology"},{"key":"25191_CR3","unstructured":"American Cancer Society. Cancer Facts & Figs. (2022)."},{"key":"25191_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canep.2018.12.001","volume":"58","author":"I Aier","year":"2019","unstructured":"Aier, I., Semwal, R., Sharma, A. & Varadwaj, P. K. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiol. 58, 104\u2013110 (2019). https:\/\/doi.org\/10.1016\/j.canep.2018.12.001 Preprint at.","journal-title":"Cancer Epidemiol."},{"key":"25191_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: global Trends, etiology and risk factors. World J. Oncol. 10, 10\u201327 (2019).","journal-title":"World J. Oncol."},{"key":"25191_CR6","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan, A. et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 24, 4846\u20134861 (2018).","journal-title":"World J. Gastroenterol."},{"key":"25191_CR7","volume-title":"Cancer Chemotherapy","author":"MT Amjad","year":"2022","unstructured":"Amjad, M. T., Chidharla, A. & Kasi, A. Cancer Chemotherapy (StatPearls Publishing LLC, 2022)."},{"key":"25191_CR8","doi-asserted-by":"publisher","DOI":"10.15761\/ICST.1000109","author":"V Lavanya","year":"2014","unstructured":"Lavanya, V., Adil, M., Ahmed, N., Rishi, A. K. & Jamal, S. Integrative cancer science and therapeutics small molecule inhibitors as emerging cancer therapeutics. Integr. Cancer Sci. Th. https:\/\/doi.org\/10.15761\/ICST.1000109 (2014).","journal-title":"Integr. Cancer Sci. Th."},{"key":"25191_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/jcb.25782","volume":"118","author":"N Khera","year":"2017","unstructured":"Khera, N. & Rajput, S. Therapeutic potential of small molecule inhibitors. J. Cell. Biochem. 118, 959\u2013961 (2017).","journal-title":"J. Cell. Biochem."},{"key":"25191_CR10","doi-asserted-by":"crossref","unstructured":"Liu, G., Chen, T., Zhang, X., Ma, X. & Shi, H. Small molecule inhibitors targeting the cancers. MedComm (Beijing).\u00a03\u00a0(2022).","DOI":"10.1002\/mco2.181"},{"key":"25191_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/jcm10040566","volume":"10","author":"A Garcia-Sampedro","year":"2021","unstructured":"Garcia-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I. & Acedo, P. The State-of-the-Art of phase II\/III clinical trials for targeted pancreatic cancer therapies. J. Clin. Med. 10, 566 (2021).","journal-title":"J. Clin. Med."},{"key":"25191_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day, C. P., Merlino, G. & Van Dyke, T. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell 163, 39\u201353. https:\/\/doi.org\/10.1016\/j.cell.2015.08.068 (2015).","journal-title":"Cell"},{"key":"25191_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50740","author":"MV Guerin","year":"2020","unstructured":"Guerin, M. V., Finisguerra, V., Van den Eynde, B. J., Bercovici, N. & Trautmann, A. Preclinical murine tumor models: A structural and functional perspective.. Elife https:\/\/doi.org\/10.7554\/eLife.50740 (2020).","journal-title":"Elife"},{"key":"25191_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/MPA.0000000000001335","volume":"48","author":"JL Saloman","year":"2019","unstructured":"Saloman, J. L. et al. nimal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer. Pancreas 48, 759\u2013779. https:\/\/doi.org\/10.1097\/MPA.0000000000001335 (2019).","journal-title":"Pancreas"},{"key":"25191_CR15","first-page":"Preprintathttps","volume":"18","author":"N du Sert","year":"2020","unstructured":"du Sert, N. et al. (ed, P.) Reporting animal research: explanation and elaboration for the arrive guidelines 2.0. PLoS Biol. 18 Preprintathttpsdoiorg101371journalpbio3000411 (2020).","journal-title":"PLoS Biol."},{"key":"25191_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71 https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ n71"},{"key":"25191_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M. & Altman, D. G. Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160, 1577\u20131579. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00872.x (2010).","journal-title":"Br J Pharmacol"},{"key":"25191_CR18","doi-asserted-by":"crossref","unstructured":"McGuinness, L. A. & Higgins, J. P. T. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods.\u00a0(2020).","DOI":"10.1002\/jrsm.1411"},{"key":"25191_CR19","unstructured":"Camarades Berlin & Quest-Bih Charit\u00e9. Preclinical systematic reviews & Meta-Analysis Wiki. https:\/\/www.CAMARADES.de (2024)."},{"key":"25191_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","volume":"39","author":"EL Deer","year":"2010","unstructured":"Deer, E. L. et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39, 425\u2013435 (2010).","journal-title":"Pancreas"},{"key":"25191_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/0192623313508250","volume":"42","author":"LC Murtaugh","year":"2014","unstructured":"Murtaugh, L. C. Pathogenesis of pancreatic cancer. Toxicol. Pathol. 42, 217\u2013228 (2014).","journal-title":"Toxicol. Pathol."},{"key":"25191_CR22","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.gendis.2025.101520","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu, M. & Yang, X. Patient-derived xenograft models: current status, challenges, and innovations in cancer research. Genes Dis. 12, 101520 (2025).","journal-title":"Genes Dis."},{"key":"25191_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal. Transduct. Target. Ther. 8, 160 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"25191_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1590\/s1806-37562018000000164","volume":"44","author":"CM Patino","year":"2018","unstructured":"Patino, C. M. & Ferreira, J. C. Internal and external validity: can you apply research study results to your patients? Jornal Brasileiro De Pneumologia. 44, 183 (2018).","journal-title":"Jornal Brasileiro De Pneumologia"},{"key":"25191_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjos-2021-100219","author":"AAM Russell","year":"2022","unstructured":"Russell, A. A. M., Sutherland, B. A., Landowski, L. M., Macleod, M. & Howells, D. W. What has preclinical systematic review ever done for us?. BMJ Open Sci. https:\/\/doi.org\/10.1136\/bmjos-2021-100219 (2022).","journal-title":"BMJ Open Sci."},{"key":"25191_CR26","doi-asserted-by":"publisher","first-page":"e89981","DOI":"10.1371\/journal.pone.0089981","volume":"9","author":"J van Luijk","year":"2014","unstructured":"van Luijk, J. et al. Systematic reviews of animal Studies; missing link in translational research? PLoS One. 9, e89981 (2014).","journal-title":"PLoS One"},{"key":"25191_CR27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1097\/j.pain.0000000000001974","volume":"161","author":"N Soliman","year":"2020","unstructured":"Soliman, N., Rice, A. S. C. & Vollert, J. A practical guide to preclinical systematic review and meta-analysis. Pain 161, 1949\u20131954 (2020).","journal-title":"Pain"},{"key":"25191_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.21037\/cdt-24-413","volume":"14","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. Reporting quality of animal research in journals that published the ARRIVE 1.0 or ARRIVE 2.0 guidelines: a cross-sectional analysis of 943 studies. Cardiovasc. Diagn. Ther. 14, 1070\u20131082 (2024).","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"25191_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/jcbfm.2014.28","volume":"34","author":"ES Sena","year":"2014","unstructured":"Sena, E. S., Currie, G. L., McCann, S. K., Macleod, M. R. & Howells, D. W. Systematic reviews and Meta-Analysis of preclinical studies: why perform them and how to appraise them critically. J. Cereb. Blood Flow. Metabolism. 34, 737\u2013742 (2014).","journal-title":"J. Cereb. Blood Flow. Metabolism"},{"key":"25191_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41231-023-00151-x","volume":"8","author":"JM Tenorio-Pedraza","year":"2023","unstructured":"Tenorio-Pedraza, J. M., Lippert, J., Burghaus, R. & Scheerans, C. R. E. S. E. A. R. C. H. Open access Meta-analysis of preclinical measures of efficacy in immune checkpoint Blockade therapies and comparison to clinical efficacy estimates. Transl Med. Commun. 8, 17 (2023).","journal-title":"Transl Med. Commun."},{"key":"25191_CR31","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne, J. A. C. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343, d4002\u2013d4002 (2011).","journal-title":"BMJ"},{"key":"25191_CR32","doi-asserted-by":"publisher","first-page":"e1000245","DOI":"10.1371\/journal.pmed.1000245","volume":"7","author":"HB van der Worp","year":"2010","unstructured":"van der Worp, H. B. et al. Can animal models of disease reliably inform human studies? PLoS Med. 7, e1000245 (2010).","journal-title":"PLoS Med."},{"key":"25191_CR33","doi-asserted-by":"publisher","first-page":"e1000344","DOI":"10.1371\/journal.pbio.1000344","volume":"8","author":"ES Sena","year":"2010","unstructured":"Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W. & Macleod, M. R. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 8, e1000344 (2010).","journal-title":"PLoS Biol."},{"key":"25191_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/ilar\/ilu043","volume":"55","author":"RBM de Vries","year":"2014","unstructured":"de Vries, R. B. M. et al. The usefulness of systematic reviews of animal experiments for the design of preclinical and clinical studies. ILAR J. 55, 427\u2013437 (2014).","journal-title":"ILAR J."},{"key":"25191_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal. Transduct. Target. Ther. 6, 201 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"25191_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF02924225","volume":"7","author":"B Pansky","year":"1990","unstructured":"Pansky, B. Anatomy of the pancreas. Int. J. Pancreatol. 7, 101\u2013108 (1990).","journal-title":"Int. J. Pancreatol."},{"key":"25191_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.mpsur.2019.04.008","volume":"37","author":"V Mahadevan","year":"2019","unstructured":"Mahadevan, V. Anatomy of the pancreas and spleen. Surg. (Oxford). 37, 297\u2013301 (2019).","journal-title":"Surg. (Oxford)"},{"key":"25191_CR38","unstructured":"National Library of Medicine NIH. About ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ at <\u2009https:\/\/clinicaltrials.gov\/search?cond=Pancreatic%20Cancer&term=Pancreas%20Cancer&intr=small%20molecule>\u00a0(2024)."},{"key":"25191_CR39","unstructured":"National Cancer Institute NIH. Drugs Approved for Pancreatic Cancer.\u00a0https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/pancreatic at https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/olaparib (2024)."},{"key":"25191_CR40","unstructured":"Villwock, S., Mirzaei, Y., Dahl, E. & Steitz, J. Experimental pancreatic cancer mouse models for treatment with small molecule inhibitors: A systematic review and meta-analysis. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=314932 (2022)."},{"key":"25191_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans, C. R. et al. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol https:\/\/doi.org\/10.1186\/1471-2288-14-43 (2014).","journal-title":"BMC Med. Res. Methodol"},{"key":"25191_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen, J. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 20, 37\u201346 (1960).","journal-title":"Educ. Psychol. Meas."},{"key":"25191_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis, J. R. & Koch, G. G. The measurement of observer agreement for categorical data. Biometrics 33, 159 (1977).","journal-title":"Biometrics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25191-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:26:41Z","timestamp":1781612801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25191-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25191"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25191-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The manuscript has been submitted with the consent of all authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"37358"}}